Современное Состояние Проблемы Моделирования Сахарного Диабета

Ozerova, I. V.; Taraban, K. V.; Ягубова, Светлана Сергеевна; Ostrovskaia, R U

doi:10.30906/0869-2092-2017-80-12-35-43

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…На этом фоне неизменный интерес вызывает экспериментальное моделирование сахарного диабета у лабораторных животных для исследования патогенеза заболевания и доклинического изыскания перспективных лекарств. Сегодня известно около двух десятков способов индукции сахарного диабета в эксперименте [4][5][6]. Особую популярность имеет применение стрептозотоцина, алкилирующего агента, являющегося произ-водным нитрозомочевины и вызывающего необратимое повреждение β-клеток поджелудочной железы [4,6].…”

Section: введение / Introductionunclassified

“…В этой связи, стрептозотоциновой диабет преимущественно рассматривают как модель диабета первого типа. Ряд авторов считает, что в зависимости от использованной дозы и режима введения стрептозотоцином можно смоделировать сахарный диабет второго типа или какой-то промежуточный вариант, сочетающий признаки сахарного диабета первого и второго типа [4,5]. При этом в каждом конкретном случае не исключена зависимость проявления диабетогенного действия от избранной линии и/или вида животных, их пола, возраста, условий содержания и других привходящих факторов.…”

Section: введение / Introductionunclassified

See 1 more Smart Citation

Manifestation of pathognomonic signs in modeling diabetes mellitus with streptozotocin in BALB/c mice

Сорокина

Жанатаев

Chayka

et al. 2023

Fk&Fd

View full text Add to dashboard Cite

Relevance. Diabetes mellitus is a widespread, socially significant disease. In this regard, it is important to obtain an experimental model that precedes subsequent experiments on pharmacological screening and/or study of the mechanism of action of antidiabetic agents.The aim of this work was a comparative assessment of the manifestation of hyperglycemia, DNA damage, and morphology of internal organs in BALB/c mice in the modeling of diabetes mellitus by a single administration of streptozotocin at a dose of 200 mg/kg and its fractional, five-day administration at a rate of 40 mg/kg per day.Methods. Streptozotocin was used as an inducer of diabetes. The drug was administered to mice once at a dose of 200 mg/kg or 5 times daily at a dose of 40 mg/kg. We monitored hyperglycemia, DNA damage in the cells of the brain, liver, kidneys, pancreas and testes, and also assessed the microscopic picture of individual internal organs, including the pancreas.Results. In both variants of the experiment, the reproduction of pathognomonic signs of diabetes mellitus is traced. They are somewhat more clearly seen in the variant of the experiment with a fractional, five-day administration of streptozotocin in single doses of 40 mg/kg.

show abstract

Section: введение / Introductionunclassified

Manifestation of pathognomonic signs in modeling diabetes mellitus with streptozotocin in BALB/c mice

Сорокина

Жанатаев

Chayka

et al. 2023

Fk&Fd

View full text Add to dashboard Cite

show abstract

Damage to Nuclear and Mitochondrial DNA in Different Organs in Streptozotocin-Induced Diabetes Models in BALB/c Mice

et al. 2023

View full text Add to dashboard Cite

Induction of hyperglycemia and accompanying biochemical and genotoxic changes in mice of different strains by tyloxapol

Kachalov,

Solomina,

Rodina

et al. 2024

Mol Med Rus

View full text Add to dashboard Cite

Introduction. Hyperglycemia inducers, the «classic» diabetogens streptozotocin and alloxan have a pronounced effect and are therefore limited suitable for modeling mild hyperglycemia in an experiment. Tyloxapol (Triton WR1339) was chosen as an alternative agent for modeling a moderate increase in blood glucose concentration in experimental animals based on literature data. The purpose of the study. The aim of the work was to investigate the possibility of tyloxapol to induce hyperglycemia and concomitant biochemical and genotoxic changes in mice of the common C57BL/6, CBA/lac and ICR lines. Methods. Hyperglycemia was modeled by single or multiple administration of tiloxapol at a dose of 400 mg/kg intraperitoneally. 24 hours after the last injection of tyloxapol, glucose and lipid levels were determined in mouse blood samples, DNA damage was assessed in organs by the DNA comet method, and chromosomal aberrations were recorded in bone marrow cells. Results. It was found that tyloxapol at a dose of 400 mg/kg with different modes of administration to mice of different lines similarly causes moderate hyperglycemia and a significant increase in triglycerides, total cholesterol and low-density lipoproteins, as well as an increase in DNA damage, which is considered as a trigger for many complications in diabetes. Conclusion. The data obtained in mice are consistent with the literature data on the hyperglycemic activity of tyloxapol, previously established in rats, and demonstrate characteristic biochemical and genotoxic effects in mice of different lines, with less severity in animals of the ICR line. In general, the data obtained indicate the possibility of using tiloxapol to model experimental diabetes in mice.

show abstract

Современное Состояние Проблемы Моделирования Сахарного Диабета

Cited by 3 publications

References 0 publications

Manifestation of pathognomonic signs in modeling diabetes mellitus with streptozotocin in BALB/c mice

Manifestation of pathognomonic signs in modeling diabetes mellitus with streptozotocin in BALB/c mice

Damage to Nuclear and Mitochondrial DNA in Different Organs in Streptozotocin-Induced Diabetes Models in BALB/c Mice

Induction of hyperglycemia and accompanying biochemical and genotoxic changes in mice of different strains by tyloxapol

Contact Info

Product

Resources

About